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Abstract Modern therapy for rheumatoid arthritis (RA)
is based on knowledge of the severity of the natural history
of the disease. RA patients are approached with early and
aggressive treatment strategies, methotrexate as an anchor
drug, biological targeted therapies in those with inadequate
response to methotrexate, and ‘‘tight control,’’ aiming for
remission and low disease activity according to quantita-
tive monitoring. This chapter presents a rationale for
current treatment strategies for RA with antirheumatic
drugs, a review of published reports concerning treatments
in clinical cohorts outside of clinical trials, and current
treatments at 61 sites in 21 countries in the QUEST-RA
database.
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Introduction
The history of rheumatoid arthritis (RA) includes a long
period from the 1950s through to the mid-1980s in which
RA was regarded ‘‘in the majority of patients as a disease
with a good prognosis,’’ based on epidemiological data [1].
This traditional teaching was that RA could be controlled
in most patients with bed rest [2], aspirin, and later with
alternative nonsteroidal anti-inﬂammatory drugs. However,
it was recognized during the mid-1980s from clinical
cohorts that short-term drug efﬁcacy was not translated
into long-term effectiveness, as most patients experienced
severe functional declines [3], radiographic progression
[4], work disability [5], and premature mortality [3]. These
reports led to calls for early and aggressive use of dis-
ease modifying anti-rheumatic drugs (DMARDs) [6–8],
including aggressive strategies to prevent future damage
and functional loss [7].
Gold sodium thiomalate was among the ﬁrst drugs to be
shown to be disease-modifying over the long term [9]. One
of the earliest proposals for a more active treatment strat-
egy in early RA was presented by Luukkainen et al. in
1978: ‘‘...In our opinion gold treatment ought to be started
in the early stages of RA, before the development of ero-
sions. We are treating not only the actual inﬂammation of
the joints but also the quality of the patient’s life for many
decades in the future’’ [10].
Currently, a strategy of early, aggressive and continuous
treatment is the basis for therapies for early RA. This
approach aims to reduce and possibly prevent damage to
joints and other organs in most patients, analogous to the
‘‘tight control’’ of hypertension and diabetes [11], in which
reducing elevated blood pressure or blood glucose (which
are consequences of a dysregulation) reduces vascular
damage and mortality rates. Lifelong therapy for RA is
required in most cases, such as in hypertension and dia-
betes. Although the etiology of the dysregulation remains
unknown in RA, the outlook for patients at this time is
much better than in previous decades in many countries.
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until the mid-1980s was based in part on evidence that
many patients with inﬂammatory arthritis in population-
based studies have a self-limited process rather than a
progressive disease [12–15]. During the mid-1980s, it
became apparent that most patients who present with
symptoms in medical settings for longer than 3–6 months
rarely experienced spontaneous remission [16, 17]. Fur-
thermore, short-term drug efﬁcacy of traditional DMARDs
such as antimalarials and penicillamine, although signiﬁ-
cantly efﬁcacious compared to placebo in clinical trials,
had low rates of long-term effectiveness and/or high rates
of toxicity, and did not prevent joint damage and poor
outcomes [3, 18].
The contemporary approach applied to patients is based
on the early use of available therapies, often in combina-
tion, to control inﬂammation as completely as possible;
tight control according to quantitative monitoring in order
to prevent long-term damage; the use of methotrexate as
the anchor drug, as it is a far more effective and less toxic
drug in the long term than earlier DMARDs; biological
agents in about 20–30% of patients with inadequate
responses to methotrexate; and an individualized approach
to speciﬁc patients.
General principles of drug therapy for RA
Several general principles characterize the contemporary
approach to patients with RA, as described below.
Early treatment
The term ‘‘rheumatoid arthritis’’ is used to describe a
syndrome that has the capacity to lead to a destructive
symmetrical polyarthritis [19]. Identiﬁcation of RA in the
early stages is both important and difﬁcult. Criteria for RA
have been developed since 1907 [20]. However, even the
most recent criteria, the American Rheumatism Associa-
tion (now the American College of Rheumatology) ACR
1987 revised criteria [21], do not differentiate patients with
early RA from other types of recent onset inﬂammatory
polyarthritides [22, 23]. Laboratory tests, which are tradi-
tionally emphasized by general physicians at the ‘‘front
line’’ of diagnosis, are normal in about 40% of patients
with RA [24, 25], including ESR, CRP, RF and anti-CCP,
so that any patient with polyarthritis for longer than two
weeks should be evaluated by a rheumatologist.
A ‘‘preventive’’ effort to reduce or avoid damage
through the control of inﬂammation should begin as soon
as there is evidence of joint swelling, and causes other than
RA, such as infection, crystal arthropathy and reactive
arthritis, have been excluded. Some patients may be treated
unnecessarily using a ‘‘preventive’’ approach. However,
the risks of ‘‘side effects’’ of RA are substantially greater
than side effects of contemporary DMARDs [26]. Early
treatment may prevent the development of RA [27],
whereas even a short delay of therapy of four months
reduces the likelihood of achieving remission [28].
Tight control
Therapy to control inﬂammation should be directed at
‘‘tight control,’’ with a goal of ‘‘preventing’’ joint damage
and other undesirable consequences. Improvement at a
20% level (ACR 20) versus a placebo is sufﬁcient for
approval of marketing through the Food and Drug
Administration (FDA), but this level of control is usually
not sufﬁcient to prevent long-term damage, which requires
more extensive control of inﬂammation in most patients.
Several studies provide strong evidence that ‘‘target
control’’ or remission is associated with better outcomes
than ACR 20 or ACR 50 responses. The FIN-RACo trial
included patients with early active RA with remission as
a treatment goal. Among patients whose inﬂammation
was controlled to a status of remission at six months, at
ﬁve years, no patient was receiving work disability pay-
ments [29]. By contrast, 22% of patients who had ACR 20
or 50 responses and 54% of patients who did not have ACR
20 responses were receiving work disability payments at
ﬁve years. The TICORA study documented that a strategy
of intensive tight control of RA led to signiﬁcantly better
status compared to traditional therapeutic strategies in
articular, functional, and radiographic outcomes over
18 months [30]. The goal of total remission is desirable,
although ‘‘low disease activity’’ status may be acceptable
for many patients, as a gold standard measure of remission
does not exist [31].
Methotrexate as an ‘‘anchor drug’’
The ‘‘anchor drug’’ for most patients with RA is weekly
low-dose methotrexate [32–34], the most effective
DMARD, with the lowest level of toxicities, particularly
with use of concomitant folic acid. The better long-term
drug continuation of methotrexate compared to other
traditional DMARDs is an indication of the beneﬁcial
efﬁcacy/tolerability proﬁle of methotrexate [35, 36].
Weekly low-dose methotrexate for RA is anti-inﬂamma-
tory, in contrast to high-dose methotrexate, which is
cytotoxic, and associated with much higher levels of
adverse events than lower doses. A large fraction of
patients are controlled adequately with methotrexate alone
or in combination with traditional DMARDs such as sul-
fasalazine and/or hydroxychloroquine, and do not appear to
require biological agents [37].
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should be kept in mind that results of randomized con-
trolled clinical trials and clinical observational studies are
presented for groups of patients, and responses of indi-
vidual patients to different agents vary considerably. In
general, it is desirable for all patients with RA to take as
high a dose of weekly methotrexate as needed or tolerated
(up to 25–30 mg). Methotrexate should be discontinued at
least three months before planned conception, and should
be used with caution in patients with liver disease or
chronic alcoholism. Methotrexate should not be discon-
tinued because of modest (\2.5 times the upper limit of
reference values) elevations of liver function tests (usually
alanine aminotranferase)—often reducing the dose corrects
the abnormality.
Biological agents
Five biological agents, including three which interfere with
the actions of tumor necrosis factor alpha (TNFa)—eta-
nercept, inﬂiximab, and adalimumab, one with T-cell
actions—abatacept, and one with B-cell actions—ritux-
imab, are approved for use in RA in the US and other
countries. These agents represent a major advance for
the armamentarium of antirheumatic drugs for patients who
have poor or incomplete responses to methotrexate
monotherapy or a combination with other DMARDs. It is
important to recognize such incomplete responses within
3–6 months of treatment, to prevent long-term damage in
the 20–30% of patients who appear to require biological
agents to control inﬂammatory activity [38]. According
to guidelines in many countries, biological agents should
be considered if patients do not respond to traditional
DMARDs including methotrexate during the ﬁrst few
months [32, 39].
The use of glucocorticoids
Long-term high-dose glucocorticoid therapy ([10 mg
equivalent of prednisone daily, for more than a few weeks)
should be avoided in the treatment of RA. By contrast, the
beneﬁts of low-dose glucocorticoid therapy, in doses of
5 mg or less, are often greater than their potential harm,
and may be continued over many years, particularly if the
bones are protected with therapy for osteopenia. However,
long-term low-dose use of glucocorticoid therapy remains
controversial [32].
Improved outcomes of RA
Evidence is increasing of improved clinical status of RA
patients at this time compared to previous decades,
according to disease activity [40, 41], functional capacity
[41–44], radiographic scores [41, 45, 46], the need for joint
replacement surgery [47], and other clinical measures [41],
including lower mortality rates in patients who responded
to methotrexate [48, 49] and lower work disability rates
in patients who responded to DMARDs [29]. These
improvements are associated with early, aggressive treat-
ment strategies in these countries. However, other reasons
cannot be excluded, such as observations of less severe
RA in the Western world compared to the past [50, 51].
Nonetheless, high disease activity is still observed in the
majority of patients in many countries and in some patients
in all countries [52].
Treatments for RA in selected clinical cohorts
and cross-sectional studies
The initial DMARD for early RA
Few DMARDs were available for RA before the 1980s. If a
DMARD was begun in early RA, it was most often intra-
muscular gold [36, 45, 53] (Table 1). During the 1980s–
1990s, sulfasalazine was used as the ﬁrst DMARD in most
European countries [46, 54–56], while methotrexate was
the ﬁrst DMARD used, and was the anchor drug for RA, in
many US rheumatology clinics [57–59], and is expanding
to other clinics and other countries [33, 60]. However, in
many published reports from the late 1990s and early
2000s, fewer than one third of patients began methotrexate
as the initial treatment for early RA (Table 1). Biological
agents were not used as the initial treatment for RA in the
reviewed data because in many countries national guide-
lines allow biological agents to be used only after the
failure of traditional DMARDs, as discussed above.
The use of DMARDs in selected early RA cohorts
The earliest cohort to enrol patients with early RA was
established in Bath, UK, between 1957 and 1963 [61]. The
use of DMARDs has been reported for over 40 years; over
that time period 46% of patients took intramuscular gold,
70% antimalarials, 3% sulfasalazine, and 4% methotrexate
[62]; 20% did not take any DMARDs. Another early RA
cohort was established in Heinola, Finland in 1973–1975.
Thiscohortenrolled103patients[63],whowerereviewed1,
3, 8, 15, 20, and 25 years after enrollment [64]. The treat-
ment strategy in the Heinola Cohort was ‘‘early and active’’
therapy. Onadmission,56%ofpatients began intramuscular
gold and 36% began antimalarials. After eight years, 24%
were taking intramuscular gold, 25% antimalarials, and 8%
other DMARDs [45, 65]. Although the treatment strategy
was active over the ﬁrst few years, long-term beneﬁts were
limitedduetodiscontinuationofthedrugs.Therefore,severe
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over the subsequent 20 years [64–66].
Patients with early RA were enrolled in an early RA
cohort in Nijmegen, the Netherlands, in 1985 [67]. Sulfa-
salazine remained the most commonly used DMARD over
ﬁve years in each of the ﬁve-year sub-cohorts (1985–1990;
1991–1995; 1996–2000) [56]. The ﬁve-year use of MTX
increased from \10% of time in the earliest cohort to
[20% in the latest cohort.
Increased use of MTX was seen in the early RA cohort
established in Jyva ¨skyla ¨ in 1996–1997 [68]. Although
these patients began with sulfasalazine as the ﬁrst DMARD
[46], after six months, two years, and ﬁve years, 24, 50,
and 70%, respectively, were taking methotrexate alone or
in combination with other DMARDs. In an early RA cohort
from a US private practice, 83% started methotrexate as the
ﬁrst DMARD for early RA in 1998–2001, and 89% had
taken methotrexate during the ﬁrst year [69].
Trends in the use of DMARDs
The use of methotrexate for the treatment of RA did not
begin until the 1990s in many countries [70, 71]. In a survey
from the USA, RA patients were taking methotrexate on
0.6% of visits in 1980–1981, 4.9% of visits in 1985, 9.1% of
visits in 1989–1991, and 27.3% of visits in 1993–1999. In
Table 1 The initial DMARD in selected early rheumatoid arthritis cohorts, according to the time period
Country Cohort,
[reference]
Enrollment
period
Percentage of patients who started selected DMARDs
IM gold
(%)
AM
(%)
SSZ
(%)
MTX
(%)
Other
DMARDs
(%)
No
DMARDs
(%)
1970s
Finland Heinola Cohort, Jantti et al. [76] 1973–1975 56 36 0 0 4 4
1980s
Finland Jyvasyla Cohort1983–1985
Sokka et al. [46]
1983–1985 70 30 0 0 0 0
Austria Aletaha et al. [53] 1985 87 7 0 0 6
NL Welsing et al. [56] 1985–1990 Na Na 60 2 38
Early 1990s
Austria Aletaha et al. [53] 1992 20 46 22 4 8
NL Welsing et al. [56] 1991–1995 Na Na 82 9 9
UK ERAS, Young et al. [77] Before 1994 8 2 61 2 11 16
UK
aNOAR, Bukhari et al. [78] Early 1990s 3 4 37 3 1 52
Greece Papadopoulos et al. [79] 1987–1995 5 30 0 21 44 0
USA Western Consortium,
Paulus et al. [80]
1993–1996 4 17 7 36 0 36
Sweden BARFOT, Forslind et al. [81] 1993–1997 0 0 34 24 8 34
Late 1990s
Finland Jyvaskyla Cohort 1995–1996,
Sokka et al. [46]
1995–1996 3 1 95 1 0 0
Finland Jyvaskyla 1997,
Makinen et al. [82]
1997 Na Na 73 20 6 1
Sweden Carli et al. [83] 1997 Na Na 30 23 11 33
Austria Aletaha et al. [53] 1998 1 40 29 29 1
NL Welsing et al. [56] 1996–2000 Na Na 76 10 14
Early 2000s
USA ERATER, Sokka and Pincus [69] 1998–2003 0 7 1 82 3 7
Sweden Carli et al. [83] 2001 Na Na 20 54 6 17
USA SONORA, Bombardier et al. [84] Early 2000s 0 16 5 27 17 35
Italy GIARA, CER [85]
b2001–2002 Na 18 1.2 19 11 51
Data for ‘‘other DMARDs’’ and ‘‘no DMARDs’’ were combined when detailed data were not available
IM gold intramuscular gold, AM antimalarials, SSZ sulfasalazine, MTX methotrexate, Na not available, NL The Netherlands
a Early inﬂammatory polyarthritis
b Early RA patients in the cohort included
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123Table 2 The DMARD proﬁle in selected clinical cohorts and clinical databases, according to the time period
Country Register or cohort,
[reference]
Study period Percentage of patients taking selected DMARDs Total
IM gold
(%)
AM
(%)
SSZ
(%)
MTX
(%)
Biol
(%)
Other
DMARD
(%)
No
DMARD
(%)
1970s
UK Bath, Rasker et al. [86] 15-yr follow-up 35 55 0 0 0 13 Na Ever used
USA Nashville, TN, Pincus et al. [3] 1973 60 26 0 0 0 Na Na Ever used
1980s
Norway Tromsø, Riise et al. [87] Year of diagnosis
1979–1987
40 39 8 7 0 45 Na % of started
DMARDs
USA Nashville, TN, Pincus et al.
[41]
1985 10 5 0 10 0 9 66 100%
UK GPRD database, Edwards et al.
[88]
1987 13 0 32 2 0 14 39 100%
Finland Jyva ¨skyla ¨ Cohort 1983–1985,
Sokka et al. [46]
1988–1990 19 7 9 12 0 30 23 100%
NL Leiden, van Schaardenburg
et al. [89]
1989–1990 25 63 3 0 0 9 Na Ever used
Early 1990s
Norway Tromsø, Riise et al. [87] Year of diagnosis
1988–1996
12 29 24 40 0 48 Na % of started
DMARDs
Japan Tokushima, Hamada et al. [90] Enrollment
1980–1990
41 0 17 22 0 [63 0
aEver used
Finland Jyva ¨skyla ¨ Cohort 1988–1999,
Sokka et al. [46]
1993–1994 24 0 15 18 0 14 29 100%
Late 1990s
Finland Heinola, Ja ¨ntti et al. [65] 1995–1996 16 13 19 12 0 40 100
UK London, Gordon et al. [91] 1996 18 12 15 36 0 8 11 100%
Norway Oslo RA register, Kvien [92] 1996–1997 47 35 35 49 0 Na 18 Ever used
Sweden Malmo ¨ RA register, So ¨derlin
et al. [93]
1997 Na Na Na 24 0 28 48 100%
USA Western Consortium, Paulus
et al. [80]
1995–1998 0 31 12 57 0 Na Na 100%
Sweden BARFOT, Forslind et al. [81] 1997 Na Na 15 33 0 19 33 100%
UK Bath, Minaur et al. [62] 40-year follow-
up
46 70 3 4 0 34 20 Ever used
Sweden Lund, Eberherdt et al. [94],
Lindqvist et al. [95]
1999 5 26 11 15 0 43 25 Ever used
Lithuania Vilnius, Dadoniene et al. [96] 1999 28 50 49 36 0 35 6 Ever used
Spain EMECAR, Gonzalez-Alvaro
[97]
1999–2000 6 8 3 32 0
b28 23 100%
Early 2000s
USA Nashville, TN, Pincus et al.
[41]
2000 1 4 0 73 4 5 13 100%
USA ERATER Sokka and Pincus
[69]
2001 0 16 4 89 14 22 Na Ever used
Finland Jyvaskyla, Cohort 1995–1996,
Sokka et al. [46]
2000–2001 7 2 10 69 1 0 11 100%
Germany National database, Thiele et al.
[98]
c2001 2 5 7 56 4 17 9 100%
Norway Norwegian DMARD register,
Kvien et al. [99]
2001 Na Na 24 38 10 28 – 100%
Sweden Malmo ¨ RA register, So ¨derlin
et al. [93]
2002 Na Na Na 44 14 11 31 100%
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use of methotrexate increased from 6% in patients who
were diagnosed in the 1970s versus 45% in the 1990s,
calculated as percentage of person-time in follow-up [72].
In many countries, the use of methotrexate appears have
increased to more than 50% of patients only during the
2000s (Table 2).
Limitations of available data concerning DMARDs
Quantitative data concerning patient clinical course and
DMARDs for RA are not available at all in many countries.
Most of the reported data concerning treatments for RA are
based on cohort studies from specialized clinics with
advanced treatment strategies in the US and Western
European countries. Therefore, these data represent a
small, selected minority of all patients.
A number of registries of biological agents have been
established over the last few years in many countries to
monitor patients outside of clinical trials [73]. These reg-
isters are not reviewed here as they often provide data only
from the minority of patients who were treated with bio-
logical agents.
DMARDs in QUEST-RA
A need to collect further quantitative data concerning
patients with RA seen in usual rheumatology care in many
clinics in many countries has led to development of a
program called Questionnaires in Standard Monitoring of
Patients with Rheumatoid Arthritis (QUEST-RA), which
has two goals: (1) to promote the quantitative assessment of
patients with rheumatic diseases in daily clinical practice,
and (2) to develop a database of RA patients seen in regular
care in many countries [52]. The initial design was to assess
100 patients with RA at each of three or more sites in dif-
ferent countries. Data collection was begun in January
2005. By July 2007, the program included 5,499 patients
from 61 sites in 21 countries: Argentina, Canada, Denmark,
Estonia, Finland, France, Germany, Greece, Hungary, Ire-
land, Italy, Latvia, Lithuania, the Netherlands, Poland,
Serbia, Spain, Sweden, Turkey, the United Kingdom, and
the United States. All patients were assessed according to a
standard protocol to evaluate RA (SPERA) [74].
Physicians completed three one-page forms: (a) review
of clinical features, including classiﬁcation criteria, extra-
articular features, comorbidities, and relevant surgeries; (b)
all previous and present DMARDs, their adverse events,
and reasons for discontinuation; (c) a 42-joint count [75]
which includes swollen and tender joints, as well as joints
with limited motion or deformity. The patients completed
a self-report questionnaire, which was translated into
different languages, and included the Health Assessment
Questionnaire (HAQ) to assess physical function, visual
analog scales for pain, global status, and fatigue, as well as
work status, and life-style choices such as smoking and
amount of physical exercise. Disease Activity Score-28
(DAS28) was calculated to estimate disease activity.
In the QUEST-RA patients, the use of intramuscular gold
as the ﬁrst DMARD dropped from[60% in patients who
were diagnosed with RA in the 1970s to\2% in patients
who were diagnosed with RA in the 2000s, and the use of
MTX increased from 2 to[50% as the initial DMARD.
At 61 QUEST-RA sites in 21 countries, 63% of patients
were taking methotrexate and 20% were taking biological
agents in 2005–2007, with considerable variation between
countires (Table 3). Fewer than 20% of patients were
Table 2 continued
Country Register or cohort,
[reference]
Study period Percentage of patients taking selected DMARDs Total
IM gold
(%)
AM
(%)
SSZ
(%)
MTX
(%)
Biol
(%)
Other
DMARD
(%)
No
DMARD
(%)
UK GPRD database, Edwards et al.
[88]
2002 2 8 26 30 0 2 32 100%
Norway Norwegian DMARD register,
Kvien et al. [99]
2004 Na Na 8 69 13 10 – 100%
Late 2000s
Japan IORRA, Yamanaka et al. [100] 2006 Na Na Na 59 3 27 11 100%
UAE Dubai, Badsha et al. [101] 2006 Na Na Na 29 2 11 58 100%
IM gold intramuscular gold, AM antimalarials, SSZ sulfasalazine, MTX methotrexate, boil biological agents, Na not available, NL The Neth-
erlands, GPRD Genaral Practice Research Database
a Ever used by those who continued DMARD treatment for 10 years
b Includes 21% combinations
c ‘‘MTX’’ includes combinations with MTX, and ‘‘biol’’ includes combinations with biological agents ‘‘ever used’’
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Netherlands, in contrast to 83% of patients in Lithuania.
More than 25% of the patients were taking biological agents
in the USA, France, Sweden, Ireland, and Latvia, although
the high percentage in some countries may be explained by
prior participation of some patients in randomized clinical
trials of biological agents. Fewer than 10% of patients were
taking biological agents in Serbia, Estonia, Argentina,
Turkey, Poland, and Lithuania (Table 3).
Methotrexate was taken at some time by 86% of all
patients, prednisone 72%, sulfasalazine 46%, antimalarials
42%, any biological agent by 24%, intramuscular gold by
23%, and leﬂunomide by 22% of all patients (Table 4).
Cyclosporine A, azathioprine, and D-penicillamine were
taken at sometime by 7–10% of patients (Table 4).
Conclusions
A major transformation has been seen in the drug treatment
of RA over the last few decades. Treatment with DMARDs
only after erosions, i.e., joint damage, has been replaced
by early, aggressive intervention. Judgment of efﬁcacy as
signiﬁcant differences from placebo has been replaced by
tight control of inﬂammation, with the goal of remission or
low disease activity, to prevent joint damage. Intamuscular
gold and penicillamine have been replaced by methotrexate,
as monotherapy or used in combination with sulfasalazine
and/or hydroxychloroquine, as well as targeted therapies
with biological agents. Patient outcomes appear much
improved at this time compared to earlier periods.
Table 3 Clinical characteristics and current use of prednisone, methotrexate, and biological agents in the QUEST-RA study
Country Sites Patients Female
(%)
Age
(years)
Disease
duration
(years)
DMARD
delay
(months)
Education
(years)
RF+
(%)
DAS 28 HAQ Taking now (%)
Pred MTX Any
biological
Mean Mean Median Median Median Median
Netherlands 3 317 66.3 59.2 9.2 5.5 11.0 68.8 2.9 0.8 16.1 74.1 19.6
Greece 3 300 75.7 57.9 11.8 7.0 12.0 52.1 3.1 0.3 70.7 71.3 47.0
Finland 3 304 72.4 58.5 13.5 7.0 9.0 74.8 3.1 0.6 51.0 61.5 12.5
USA 3 301 72.9 57.5 9.3 9.0 13.0 70.9 3.2 0.6 60.1 71.8 27.6
Denmark 3 301 76.7 57.8 12.0 10.1 10.0 73.3 3.3 0.6 14.6 71.1 21.3
Spain 3 302 73.5 59.8 10.6 14.0 10.0 72.5 3.4 0.9 46.7 56.3 23.2
France 4 389 77.9 55.3 12.8 8.0 10.0 75.3 3.6 0.9 60.9 57.1 44.2
Sweden 3 260 71.8 59.4 12.5 12.0 10.0 81.6 3.6 0.9 41.2 65.8 26.9
Ireland 3 240 64.3 56.4 11.3 11.0 12.0 79.6 4.0 0.8 31.3 71.7 32.1
Turkey 3 309 85.6 51.9 11.6 12.0 5.0 67.6 4.1 0.9 57.3 69.3 5.8
UK 3 145 77.9 59.6 15.0 12.0 12.0 81.4 4.1 0.9 28.3 69.7 14.5
Germany 3 225 83.6 58.8 13.4 15.0 10.0 60.9 4.3 0.8 26.7 45.8 22.7
Canada 1 100 78.8 57.4 12.4 12.0 12.0 82.8 4.3 1.0 25.0 49.0 23.0
Italy 4 336 78.2 61.0 10.5 9.0 8.0 71.4 4.5 1.1 51.8 53.3 12.5
Estonia 3 168 85.5 55.8 11.8 12.0 12.0 68.1 4.7 1.1 40.5 53.6 0.6
Latvia 1 61 80.3 52.4 13.4 23.0 12.5 81.7 5.1 1.4 55.7 75.4 27.9
Hungary 3 153 87.4 57.9 12.6 12.0 12.0 92.8 5.2 1.4 38.6 62.7 12.4
Poland 7 642 86.7 53.2 11.5 4.0 12.0 70.3 5.3 1.4 58.9 65.0 6.1
Lithuania 2 300 82.9 54.1 10.7 13.0 13.0 78.4 5.6 1.4 80.7 55.7 9.3
Argentina 2 246 90.2 51.4 9.9 13.0 9.0 90.5 5.6 1.0 63.4 48.8 2.8
Serbia 1 100 88.0 59.2 10.1 11.1 8.0 71.4 6.1 1.6 54.0 54.0 0.0
Total 61 5,499 78.6 56.7 11.5 10.0 11.0 73.2 4.1 1.0 48.6 62.5 19.0
Modiﬁed and updated from [52], with permission
Table 4 Percentage of patients
with current or previous (ever)
use of various DMARDs in
QUEST-RA, including 5,499
patients from 61 clinics in 21
countries
DMARD (%)
Prednisone 72
Intramuscular gold 23
Antimalarials 42
Sulfasalazine 46
Methotrexate 86
Any biological agent 24
Leﬂunomide 22
Cyclosporin A 9.6
Azathioprine 7.5
D-penicillamine 6.9
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123Methotrexate use may serve as an excellent indicator of
the transformation of drug therapy for RA; it was imple-
mented in only a few patients in a few clinical settings
in the 1980s, with increases in the number of clinics and
patients in the 1990s, and widespread use as the ‘‘anchor
drug’’ in most settings in the 2000s. Nonetheless, data in
published reports continue to include only a minority of all
patients with RA. Further efforts are needed to promote the
collection of quantitative data in all patients with RA, in all
countries, at all visits, in order to facilitate tight control and
better outcomes for all patients with RA.
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